{"id":"apg777","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"APG777 works by selectively inhibiting the activity of fibroblast growth factor receptors 1, 2, and 3, which are involved in the regulation of cell growth and division. This inhibition can lead to the reduction of tumor growth and metastasis. APG777 has shown promise in preclinical studies as a potential treatment for various types of cancer.","oneSentence":"APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:53.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors with FGFR alterations"}]},"trialDetails":[{"nctId":"NCT07003425","phase":"PHASE2","title":"A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis","status":"RECRUITING","sponsor":"Apogee Therapeutics, Inc.","startDate":"2025-05-14","conditions":"Atopic Dermatitis","enrollment":350},{"nctId":"NCT07027527","phase":"PHASE1","title":"An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Apogee Therapeutics, Inc.","startDate":"2025-06-04","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT06920901","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Apogee Therapeutics, Inc.","startDate":"2025-03-27","conditions":"Asthma","enrollment":31},{"nctId":"NCT06395948","phase":"PHASE2","title":"A Study Evaluating APG777 in Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Apogee Therapeutics, Inc.","startDate":"2024-04-29","conditions":"Atopic Dermatitis","enrollment":470}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"APG777","genericName":"APG777","companyName":"Apogee Therapeutics, Inc.","companyId":"apogee-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3. Used for Solid tumors with FGFR alterations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}